HNT as a Biodegradable Carrier Polymerized by Cold Atmospheric Pressure Plasma for In Vivo Release of Carboplatin and Paclitaxel

Lung cancer is the leading cause of cancer mortality worldwide. Recently, Cold atmospheric pressure plasma (CAP), plasma activated liquid (PAL), and nanomaterial have been significant advances in oncotherapy. Reactive oxygen-nitrogen species (RONS) generated by CAP interact with cells and induce selective responses between the malignant and normal cells. Halloysite clay nanotubes (HNTs) have shown potential as a drug delivery vehicle, and its surface can be modified and tailored as a targeted drug delivery system. The study aims to investigate for the first time the anti-tumor effect of CAP, PAL, and HNT is a nanocarrier for chemotherapeutic agents, on the lung cancer model in mice. In the CAP treatment modality, we set mice in contact with CAP at different times. Also, to prepare PAL we expose a Phosphate Buffered Saline (PBS) in the same conditions. To this end, mouse models tumor size evaluate after CAP, PAL, and the combination of CAP and HNT. Besides, High performance liquid chromatography, surface morphology, tissue distribution, luminescence assay, in vivo anti-angiogenesis assay perform to investigate the efficiency of the mentioned treatment modality. Also, the pH and concentration of long-lived reactive oxygen and nitrogen species have been measured. Collectively, we expect CAP as an oncotherapeutics agent is a promising method for the future combination or multimodal lung cancer oncotherapy.